No headlines found.
The Fund's investment objective is long-term capital appreciation through investment in companies in the life sciences industry (including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies), agriculture and environmental management. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. The Fund invests primarily in securities of public and private companies that are believed by the Fund's Investment Adviser, Tekla Capital Management LLC (the Adviser), to have significant potential for above-average growth. Effective October 15, 2014, the name of the Fund changed from H&Q Life Sciences Investors to Tekla Life Sciences Investors.
Tekla Life Sciences Investors trades on the NYSE stock market under the symbol HQL.
As of May 10, 2024, HQL stock price climbed to $13.85 with 148,563 million shares trading.
HQL has a beta of 0.86, meaning it tends to be less sensitive to market movements. HQL has a correlation of 0.35 to the broad based SPY ETF.
HQL has a market cap of $378.80 million. This is considered a Small Cap stock.
In the last 3 years, HQL stock traded as high as $22.70 and as low as $11.34.
HQL has underperformed the market in the last year with a return of +10.8%, while the SPY ETF gained +27.8%. In the last 3 month period, HQL fell short of the market, returning +2.7%, while SPY returned +4.2%. However, in the most recent 2 weeks HQL has outperformed the stock market by returning +6.8%, while SPY returned +2.5%.
HQL support price is $13.68 and resistance is $13.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HQL stock will trade within this expected range on the day.